Compositions, organisms and methodologies employing a novel human kinase
First Claim
Patent Images
1. An isolated polynucleotide comprising a nucleic acid sequence which encodes the amino acid sequence depicted in SEQ ID NO:
- 2.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.
15 Citations
19 Claims
- 1. An isolated polynucleotide comprising a nucleic acid sequence which encodes the amino acid sequence depicted in SEQ ID NO:
-
4. An isolated polynucleotide comprising a variant of a nucleic acid sequence, wherein said nucleic acid sequence encodes the amino acid sequence depicted in SEQ ID NO:
- 2, and wherein the variant and said nucleic acid sequence have at least 91% sequence identity.
- View Dependent Claims (5)
-
6. An isolated polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO:
- 1 or the complement thereof, wherein said polynucleotide consists of at least 1000 nucleic acids and does not include the nucleotide sequences of SEQ ID NOS;
5-8 or the complement thereof.
- 1 or the complement thereof, wherein said polynucleotide consists of at least 1000 nucleic acids and does not include the nucleotide sequences of SEQ ID NOS;
-
7. An isolated polynucleotide that hybridizes under highly stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO:
- 1 or the complement thereof, said polynucleotide consists of at least 2600 nucleic acids and encodes a protein kinase.
-
8. An antibody capable of binding to the amino acid sequence depicted in SEQ ID NO:
- 2 with a binding affinity of no less than 105 M−
1. - View Dependent Claims (9)
- 2 with a binding affinity of no less than 105 M−
-
12. A non-human animal, wherein at least one allele of a gene in the genome of said animal is functionally disrupted, and wherein said gene encodes a polypeptide that has at least 70% sequence identity to SEQ ID NO:
- 2.
-
13. A method for identifying an agent capable of binding to HPK3P23 kinase, comprising:
-
contacting a candidate agent with a polypeptide comprising;
(a) an amino acid sequence recited in SEQ ID NO;
2,(b) a fragment of SEQ ID NO;
2, or(c) a variant of (a) or (b); and
detecting the binding between said candidate agent and said polypeptide.
-
-
14. A method for identifying an agent capable of modulating the level of activity of HPK3P23 kinase, comprising:
-
contacting a candidate agent with an polypeptide comprising;
(a) an amino acid sequence recited in SEQ ID NO;
2, or(b) a biologically active portion of SEQ ID NO;
2; and
detecting a change in the level of an activity of said polypeptide.
-
- 15. A pharmaceutical composition for preventing or treating HPK3P23-related diseases, comprising a pharmaceutically acceptable carrier and an agent that modulates an HPK3P23 activity or the HPK3P23 gene expression.
- 17. A polynucleotide capable of inhibiting human HPK3P23 gene expression by RNA interference.
Specification